Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer-Reference-Cited by-同舟云学术

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer

Published:2019-05-31 Issue:18 Volume:125 Page:3155-3163
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Martini Alberto¹^ORCID,Jia Rachel²,Ferket Bart S.²,Waingankar Nikhil¹²^ORCID,Plimack Elizabeth R.³,Crabb Simon J.⁴^ORCID,Harshman Lauren C.⁵^ORCID,Yu Evan Y.⁶,Powles Thomas⁷,Rosenberg Jonathan E.⁸,Pal Sumanta K.⁹^ORCID,Vaishampayan Ulka N.¹⁰^ORCID,Necchi Andrea¹¹^ORCID,Wiklund N. Peter¹,Mehrazin Reza¹,Mazumdar Madhu²,Sfakianos John P.¹,Galsky Matthew D.¹²

Affiliation:

1. Department of Urology Icahn School of Medicine at Mount Sinai New York New York

2. Institute for Healthcare Delivery Science, Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York New York

3. Fox Chase Cancer Center Philadelphia Pennsylvania

4. University of Southampton Southampton United Kingdom

5. Dana‐Farber Cancer Institute Boston Massachusetts

6. University of Washington Seattle Washington

7. Barts Cancer Institute Queen Mary University of London London United Kingdom

8. Memorial Sloan Kettering Cancer Center New York New York

9. City of Hope Comprehensive Cancer Center Duarte California

10. Karmanos Cancer Center Wayne State University Detroit Michigan

11. National Institute for Tumors Milan Italy

12. Division of Hematology and Oncology, Department of Medicine Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York

Publisher

Wiley